{"id":1122756,"date":"2024-03-06T15:56:21","date_gmt":"2024-03-06T20:56:21","guid":{"rendered":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/uncategorized\/gilead-sciences-ceo-on-companys-evolution-and-commitment-to-the-bay-area-biospace\/"},"modified":"2024-03-06T15:56:21","modified_gmt":"2024-03-06T20:56:21","slug":"gilead-sciences-ceo-on-companys-evolution-and-commitment-to-the-bay-area-biospace","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/evolution\/gilead-sciences-ceo-on-companys-evolution-and-commitment-to-the-bay-area-biospace\/","title":{"rendered":"Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area – BioSpace"},"content":{"rendered":"

NORTHAMPTON, MA \/ ACCESSWIRE \/ March 5, 2024 \/ Gilead Sciences, Inc. Originally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.com <\/p>\n

Much has changed since Daniel O'Day, chairman and CEO, arrived at Gilead Sciences in 2019. The company has grown considerably and expanded on its long-standing leadership in antiviral therapies to include a focus on cancer medicines. Today the Foster City-based company is the second-largest biotech employer in the Bay Area, and according to a Bay Area Council report, it created an estimated economic impact of $22.1 billion in 2020 alone. It has more than 25 marketed therapies for HIV, cancer, hepatitis, COVID-19 and other diseases, and one of the strongest and most diverse pipelines of new medicines in its history. <\/p>\n

Continue reading here <\/p>\n<\/p>\n

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com. <\/p>\n

Contact Info: Spokesperson: Gilead Sciences Website: https:\/\/www.3blmedia.com\/profiles\/gilead-sciences<\/a> Email: info@3blmedia.com<\/a> <\/p>\n

SOURCE: Gilead Sciences <\/p>\n<\/p>\n

View the original press release on accesswire.com <\/p>\n<\/p>\n

<\/p>\n

Continue reading here:<\/p>\n

Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area - BioSpace<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

NORTHAMPTON, MA \/ ACCESSWIRE \/ March 5, 2024 \/ Gilead Sciences, Inc. Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187748],"tags":[],"class_list":["post-1122756","post","type-post","status-publish","format-standard","hentry","category-evolution"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1122756"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=1122756"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1122756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=1122756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=1122756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=1122756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}